ERAS (Erasca, Inc.) Pangali Forward P/E
The market trend for Erasca, Inc. (ERAS) shows a forward P/E ratio of 0.00. The company's business relies on developing drugs for targeted action on oncopathologies via the RAS/MAPK pathway, where success depends on therapeutic precision and deals with industry behemoths. Development is driven by the independent advancement of its drug portfolio, limiting partner interaction solely to joint testing of combination therapies.
Ringkesan rincian data analitis Erasca Oncology (ERAS)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Erasca, Inc.|ERAS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Erasca, Inc.|ERAS - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Erasca Inc|ERAS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Erasca|Likuiditas cepet erasca.com
- rincian asil keuangan lan kelipatan valuasi:
ERAS - Asil keuangan resik|Proyeksi bathi mangsa ngarep Erasca, Inc.|ERAS - Koefisien rega marang bathi|Pangali Forward P/E Erasca Corp|ERAS - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Erasca Inc|ERAS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Erasca|ERAS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan erasca.com|ERAS - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Erasca, Inc.
Analisis kabeh metrik perusahaan:ERAS Erasca
This indicator compares the current quote with expected annual earnings, measuring market expectations for capitalization. For Erasca, Inc. (ERAS), the metric reflects the synergy efficiency of scientific collaborations and startup acquisition strategies. By analyzing the company's 12-month forward P/E, an investor can track business valuation dynamics between quarterly reports. Sharp declines in the line signal a drop in development profitability, serving as a critical signal to revise the asset's portfolio weighting.
Pesaing langsung
Prakiraan rega marang bathi ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (RevMed)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Therapeutics (BCAX) - Rega marang bathi mangsa ngarep|Personalis Inc - Pangali mangsa ngarep rega marang bathi|DCTH (Delcath) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Y-mAbs Corp YMAB|Pangali Forward P/E AURA|CADL - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Accuray ARAY|Pangali mangsa ngarep rega marang bathi SLS|Actuate Therapeutics, Inc - Pangali Forward P/E|CTOR - Pangali Forward P/E|tuhurabio.com (HURA) - Rega marang bathi mangsa ngarep|TARA - Kapitalisasi marang proyeksi bathi|FATE (Fate Therapeutics) - Pangali Forward P/E|Prakiraan rega marang bathi Aadi Bio (WHWK)|Pangali Forward P/E TCRX|Pangali Forward P/E championsoncology.com (CSBR)|XBiotech - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CVM|OS Therapies - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi radiopharmtheranostics.com RADX|artivabio.com (ARTV) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep ANL|VERU (Veru Inc.) - Pangali Forward P/E|Prakiraan rega marang bathi tempesttx.com (TPST)|Prakiraan rega marang bathi XLO (Xilio Therapeutics, Inc.)|Kapitalisasi marang proyeksi bathi renovarobio.com|Pangali Forward P/E MURA (Mural Oncology)|Kairos Pharma Limited (KAPA) - Rasio prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi GDTC (CytoMed Therapeutics)|CRIS: Pangali Forward P/E|Apollomics (APLM) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Tharimmune Corp|Advanced Biomed Corp (ADVB) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E GNPX|Prakiraan rega marang bathi calidibio.com CLDI|Pangali Forward P/E SBFM (Sunshine Biopharma, Inc.)|Pangali Forward P/E Xenetic Biosciences Inc. XBIO|SLRX - Rega marang bathi mangsa ngarep|PPBT (Kitov Pharma) - Rasio rega marang bathi mangsa ngarep|AONC: Pangali Forward P/E|Prakiraan rega marang bathi beigene.com|CKPT (Checkpoint Therapeutics, Inc.) - Pangali Forward P/E|Rasio prakiraan rega marang bathi elevationoncology.com ELEV|Rega marang bathi mangsa ngarep iCAD, Inc. (ICAD)|IKNA (ikenaoncology.com) - Pangali mangsa ngarep rega marang bathi|Notable Labs, Ltd. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi VIRX|MorphoSys - Pangali Forward P/E|NAYA Biosciences Inc (NAYA) - Prakiraan rega marang bathi|AAPGV (Ascentage Pharma Group Ltd) - Prakiraan rega marang bathi
